Skip to content

Author

Zhao-Yang Zeng

We have 6 of 56 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

RNA 5-Methylcytosine (m5C) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation.

RNA 5-methylcytosine (m5C) has emerged as an important epitranscriptomic modification in cancer. Rather than acting as a uniformly oncogenic mark, m5C produces context-dependent effects by coupling RNA fate to cellular adaptation. Through control of RNA stability, nuclear export, translation, splicing, and RNA structur...

Jie Wu, Xiao-Gang Wang, Jun-Shang Ge et al. · 0 citations
Sep 2026

Burden of cancer in China from 1990 to 2023 and projections to 2050.

An emerging structural divergence is revealed in China's cancer burden, with incidence increasingly concentrated in women and mortality in men, and the need for sex- and age-specific cancer control strategies is highlighted.

Dan Wang, Zhen-Zhen Rao, Wei Xiong et al. · 0 citations
Review Open access Sep 2026

Neural–tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies

This review focuses on tumors arising outside the central nervous system and their bidirectional interactions with peripheral nerves, summarizing the current evidence on the molecular mechanisms underlying these reciprocal interactions.

Yu-Zhe Huang, Tong Tong, Zhao-Yang Zeng et al. · 0 citations
Sep 2026

CircRHBDD1(4,5) drives malignant progression of oral squamous cell carcinoma by enhancing DKK1 mRNA stability through facilitating m6A-dependent IGF2BP2 binding

This study identified for the first time that circRHBDD1(4,5) (hsa_circ_0058493, a 656-nt circRNA generated by back-splicing of exons 4 and 5 of the RHBDD1 gene) is markedly upregulated in OSCC and promotes tumor cell proliferation, invasion, and metastasis.

Dai-Xi Ren, Jia-Rong Zhang, Mao-Kui Huang et al. · 0 citations
Open access Aug 2026

LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma

This study uncovers a novel mechanism by which the tumor suppressor LARS2 inhibits immune evasion in NPC through upregulation of MHC-I, and highlights a high-leucine diet as a promising strategy to sensitize tumors to immunotherapy.

Mei Yang, Yongzhen Mo, Dai-Xi Ren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.